Results 371 to 380 of about 304,614 (388)

Breast cancer statistics, 2013

Ca-A Cancer Journal for Clinicians, 2014
Carol E Desantis, Ahmedin Jemal
exaly  

Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock

Critical Care Medicine, 2004
D. Konrad, A. Oldner, P. Rossi, M. Wanecek, A. Rudehill, E. Weitzberg   +5 more
semanticscholar   +1 more source

Breast cancer statistics, 2017, racial disparity in mortality by state

Ca-A Cancer Journal for Clinicians, 2017
Carol E Desantis, Ann Goding Sauer, Lisa Newman   +2 more
exaly  

Macitentan: Endothelin receptor antagonist

Pharmacy Today, 2013
openaire   +2 more sources

Breast cancer statistics, 2019

Ca-A Cancer Journal for Clinicians, 2019
Carol E Desantis, Jiemin Ma, Mia M Gaudet   +2 more
exaly  

Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

Clinical Pharmacokinetics, 2004
J. Dingemanse, P. Giersbergen
semanticscholar   +1 more source

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Journal of clinical pharmacology, 1999
C. Weber, R. Schmitt, H. Birnboeck, G. Hopfgartner, H. Eggers, Joseph Meyer, S. Marle, Henk W. Viischer, J. Jonkman   +8 more
semanticscholar   +1 more source

Gastroenteropancreatic Neuroendocrine Tumors

Ca-A Cancer Journal for Clinicians, 2018
Mauro Cives, Jonathan Strosberg
exaly  

Normalizing NADPH Oxidase Contributes to Attenuating Diabetic Nephropathy by the Dual Endothelin Receptor Antagonist CPU0213 in Rats

American Journal of Nephrology, 2008
Ming Xu, D. Dai, Yin Dai
semanticscholar   +1 more source

Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage

Expert Opinion on Investigational Drugs, 2008
R Loch Macdonald
semanticscholar   +1 more source